Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey

Jasmine Grenier; Shaun G. Goodman; Lawrence A. Leiter; Anatoly Langer; Hwee Teoh; Deepak L. Bhatt; Alice Y.Y. Cheng; Mary K. Tan; Thomas Ransom; Kim A. Connelly; Andrew T. Yan

doi:10.1016/j.jcjd.2017.01.005

Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey

Jasmine Grenier, Shaun G. Goodman, Lawrence A. Leiter, Anatoly Langer, Hwee Teoh, Deepak L. Bhatt, Alice Y.Y. Cheng, Mary K. Tan, Thomas Ransom, Kim A. Connelly, Andrew T. Yan

Medicine

Résultat de recherche: Article › examen par les pairs

13 Citations (Scopus)

Résumé

Objectives: Optimal treatment of blood pressure (BP) and other cardiovascular risk factors, including hyperglycemia, is integral to diabetes management. There are limited data from the primary care setting concerning the contemporary and comprehensive management of type 2 diabetes and other cardiovascular risk factors in relation to guideline-recommended BP target achievement. Methods: The Diabetes Mellitus Status in Canada (DM-SCAN) survey included 5172 ambulatory patients with type 2 diabetes. Data were collected on patient demographics, medical histories, medication usage, BP levels and laboratory investigations. We stratified the study population based on their attainment of the BP target recommended by the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada and the Canadian Hypertension Education Program (<130/80 mmHg) and compared patient clinical characteristics and treatments. Results: Of the 5145 patients with available BP data, 36% achieved the BP target. Prevalence of smoking, known coronary artery disease, retinopathy, neuropathy and nephropathy were similar in the groups with BP 130/80 mmHg or higher and BP 130/80 mmHg or lower. Patients with BP 130/80 mmHg or higher were taking more antihypertensive agents and were more likely to be taking angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, diuretics and calcium channel blockers. They also had significantly higher glycated hemoglobin and low-density lipoprotein-cholesterol levels. Overall, these patients were also less likely to achieve guideline-recommended glycemic and lipid targets. Conclusions: Only about one-third of patients with diabetes achieved the target BP of below 130/80 mmHg. Patients with BP 130/80 mmHg or higher were also less likely to achieve optimal guideline-recommended glycated hemoglobin and low-density lipoprotein-cholesterol targets. Improved comprehensive management of all risk factors in patients with diabetes is warranted.

Langue d'origine	English
Pages (de-à)	130-137
Nombre de pages	8
Journal	Canadian Journal of Diabetes
Volume	42
Numéro de publication	2
DOI	https://doi.org/10.1016/j.jcjd.2017.01.005
Statut de publication	Published - avr. 2018

Note bibliographique

Funding Information:
Alice Y. Cheng: Speaker, consulting honoraria, and/or research grant support from AstraZeneca, Amgen, Abbott, BD, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier, Takeda, Valeant

Funding Information:
Lawrence A. Leiter: Speaker, consulting honoraria, and/or research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmith Kline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Servier and Takeda

Funding Information:
The DM-SCAN survey was made possible through the support of Merck Canada Inc. The opinions expressed in this material are those of the authors and do not necessarily reflect the views of Merck Canada Inc. The Canadian Heart Research Centre developed the protocol, coordinated the study and collected and managed the data. We thank Sue Francis, BA, for her editorial assistance in the preparation of this manuscript. Dr. Shaun Goodman is supported by the Heart and Stroke Foundation of Ontario in his role as Heart and Stroke Foundation (Polo) Chair at the University of Toronto.

Funding Information:
Kim A. Connelly: Speaker, consulting honoraria, and/or research grant support from Astra Zeneca, Bristol Myer Squibb, Servier, Merck, Janssen and Boehringer Ingelheim.

Funding Information:
Shaun G. Goodman: Speaker, consulting honoraria, and/or research grant support from Sanofi, Bristol Myers Squibb

Publisher Copyright:
© 2017 Diabetes Canada

ASJC Scopus Subject Areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/j.jcjd.2017.01.005

Autres fichiers et liens

Citer

Grenier, J., Goodman, S. G., Leiter, L. A., Langer, A., Teoh, H., Bhatt, D. L., Cheng, A. Y. Y., Tan, M. K., Ransom, T., Connelly, K. A., & Yan, A. T. (2018). Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 42(2), 130-137. https://doi.org/10.1016/j.jcjd.2017.01.005

@article{80972bed6f0c41eb9bb96f1517716283,

title = "Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey",

abstract = "Objectives: Optimal treatment of blood pressure (BP) and other cardiovascular risk factors, including hyperglycemia, is integral to diabetes management. There are limited data from the primary care setting concerning the contemporary and comprehensive management of type 2 diabetes and other cardiovascular risk factors in relation to guideline-recommended BP target achievement. Methods: The Diabetes Mellitus Status in Canada (DM-SCAN) survey included 5172 ambulatory patients with type 2 diabetes. Data were collected on patient demographics, medical histories, medication usage, BP levels and laboratory investigations. We stratified the study population based on their attainment of the BP target recommended by the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada and the Canadian Hypertension Education Program (<130/80 mmHg) and compared patient clinical characteristics and treatments. Results: Of the 5145 patients with available BP data, 36% achieved the BP target. Prevalence of smoking, known coronary artery disease, retinopathy, neuropathy and nephropathy were similar in the groups with BP 130/80 mmHg or higher and BP 130/80 mmHg or lower. Patients with BP 130/80 mmHg or higher were taking more antihypertensive agents and were more likely to be taking angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, diuretics and calcium channel blockers. They also had significantly higher glycated hemoglobin and low-density lipoprotein-cholesterol levels. Overall, these patients were also less likely to achieve guideline-recommended glycemic and lipid targets. Conclusions: Only about one-third of patients with diabetes achieved the target BP of below 130/80 mmHg. Patients with BP 130/80 mmHg or higher were also less likely to achieve optimal guideline-recommended glycated hemoglobin and low-density lipoprotein-cholesterol targets. Improved comprehensive management of all risk factors in patients with diabetes is warranted.",

author = "Jasmine Grenier and Goodman, {Shaun G.} and Leiter, {Lawrence A.} and Anatoly Langer and Hwee Teoh and Bhatt, {Deepak L.} and Cheng, {Alice Y.Y.} and Tan, {Mary K.} and Thomas Ransom and Connelly, {Kim A.} and Yan, {Andrew T.}",

note = "Funding Information: Alice Y. Cheng: Speaker, consulting honoraria, and/or research grant support from AstraZeneca, Amgen, Abbott, BD, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier, Takeda, Valeant Funding Information: Lawrence A. Leiter: Speaker, consulting honoraria, and/or research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmith Kline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Servier and Takeda Funding Information: The DM-SCAN survey was made possible through the support of Merck Canada Inc. The opinions expressed in this material are those of the authors and do not necessarily reflect the views of Merck Canada Inc. The Canadian Heart Research Centre developed the protocol, coordinated the study and collected and managed the data. We thank Sue Francis, BA, for her editorial assistance in the preparation of this manuscript. Dr. Shaun Goodman is supported by the Heart and Stroke Foundation of Ontario in his role as Heart and Stroke Foundation (Polo) Chair at the University of Toronto. Funding Information: Kim A. Connelly: Speaker, consulting honoraria, and/or research grant support from Astra Zeneca, Bristol Myer Squibb, Servier, Merck, Janssen and Boehringer Ingelheim. Funding Information: Shaun G. Goodman: Speaker, consulting honoraria, and/or research grant support from Sanofi, Bristol Myers Squibb Publisher Copyright: {\textcopyright} 2017 Diabetes Canada",

year = "2018",

month = apr,

doi = "10.1016/j.jcjd.2017.01.005",

language = "English",

volume = "42",

pages = "130--137",

journal = "Canadian Journal of Diabetes",

issn = "1499-2671",

publisher = "Canadian Diabetes Association",

number = "2",

}

TY - JOUR

T1 - Blood Pressure Management in Adults With Type 2 Diabetes

T2 - Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey

AU - Grenier, Jasmine

AU - Goodman, Shaun G.

AU - Leiter, Lawrence A.

AU - Langer, Anatoly

AU - Teoh, Hwee

AU - Bhatt, Deepak L.

AU - Cheng, Alice Y.Y.

AU - Tan, Mary K.

AU - Ransom, Thomas

AU - Connelly, Kim A.

AU - Yan, Andrew T.

N1 - Funding Information: Alice Y. Cheng: Speaker, consulting honoraria, and/or research grant support from AstraZeneca, Amgen, Abbott, BD, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier, Takeda, Valeant Funding Information: Lawrence A. Leiter: Speaker, consulting honoraria, and/or research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmith Kline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Servier and Takeda Funding Information: The DM-SCAN survey was made possible through the support of Merck Canada Inc. The opinions expressed in this material are those of the authors and do not necessarily reflect the views of Merck Canada Inc. The Canadian Heart Research Centre developed the protocol, coordinated the study and collected and managed the data. We thank Sue Francis, BA, for her editorial assistance in the preparation of this manuscript. Dr. Shaun Goodman is supported by the Heart and Stroke Foundation of Ontario in his role as Heart and Stroke Foundation (Polo) Chair at the University of Toronto. Funding Information: Kim A. Connelly: Speaker, consulting honoraria, and/or research grant support from Astra Zeneca, Bristol Myer Squibb, Servier, Merck, Janssen and Boehringer Ingelheim. Funding Information: Shaun G. Goodman: Speaker, consulting honoraria, and/or research grant support from Sanofi, Bristol Myers Squibb Publisher Copyright: © 2017 Diabetes Canada

PY - 2018/4

Y1 - 2018/4

N2 - Objectives: Optimal treatment of blood pressure (BP) and other cardiovascular risk factors, including hyperglycemia, is integral to diabetes management. There are limited data from the primary care setting concerning the contemporary and comprehensive management of type 2 diabetes and other cardiovascular risk factors in relation to guideline-recommended BP target achievement. Methods: The Diabetes Mellitus Status in Canada (DM-SCAN) survey included 5172 ambulatory patients with type 2 diabetes. Data were collected on patient demographics, medical histories, medication usage, BP levels and laboratory investigations. We stratified the study population based on their attainment of the BP target recommended by the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada and the Canadian Hypertension Education Program (<130/80 mmHg) and compared patient clinical characteristics and treatments. Results: Of the 5145 patients with available BP data, 36% achieved the BP target. Prevalence of smoking, known coronary artery disease, retinopathy, neuropathy and nephropathy were similar in the groups with BP 130/80 mmHg or higher and BP 130/80 mmHg or lower. Patients with BP 130/80 mmHg or higher were taking more antihypertensive agents and were more likely to be taking angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, diuretics and calcium channel blockers. They also had significantly higher glycated hemoglobin and low-density lipoprotein-cholesterol levels. Overall, these patients were also less likely to achieve guideline-recommended glycemic and lipid targets. Conclusions: Only about one-third of patients with diabetes achieved the target BP of below 130/80 mmHg. Patients with BP 130/80 mmHg or higher were also less likely to achieve optimal guideline-recommended glycated hemoglobin and low-density lipoprotein-cholesterol targets. Improved comprehensive management of all risk factors in patients with diabetes is warranted.

AB - Objectives: Optimal treatment of blood pressure (BP) and other cardiovascular risk factors, including hyperglycemia, is integral to diabetes management. There are limited data from the primary care setting concerning the contemporary and comprehensive management of type 2 diabetes and other cardiovascular risk factors in relation to guideline-recommended BP target achievement. Methods: The Diabetes Mellitus Status in Canada (DM-SCAN) survey included 5172 ambulatory patients with type 2 diabetes. Data were collected on patient demographics, medical histories, medication usage, BP levels and laboratory investigations. We stratified the study population based on their attainment of the BP target recommended by the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada and the Canadian Hypertension Education Program (<130/80 mmHg) and compared patient clinical characteristics and treatments. Results: Of the 5145 patients with available BP data, 36% achieved the BP target. Prevalence of smoking, known coronary artery disease, retinopathy, neuropathy and nephropathy were similar in the groups with BP 130/80 mmHg or higher and BP 130/80 mmHg or lower. Patients with BP 130/80 mmHg or higher were taking more antihypertensive agents and were more likely to be taking angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, diuretics and calcium channel blockers. They also had significantly higher glycated hemoglobin and low-density lipoprotein-cholesterol levels. Overall, these patients were also less likely to achieve guideline-recommended glycemic and lipid targets. Conclusions: Only about one-third of patients with diabetes achieved the target BP of below 130/80 mmHg. Patients with BP 130/80 mmHg or higher were also less likely to achieve optimal guideline-recommended glycated hemoglobin and low-density lipoprotein-cholesterol targets. Improved comprehensive management of all risk factors in patients with diabetes is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85019598499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019598499&partnerID=8YFLogxK

U2 - 10.1016/j.jcjd.2017.01.005

DO - 10.1016/j.jcjd.2017.01.005

M3 - Article

C2 - 28552652

AN - SCOPUS:85019598499

SN - 1499-2671

VL - 42

SP - 130

EP - 137

JO - Canadian Journal of Diabetes

JF - Canadian Journal of Diabetes

IS - 2

ER -

Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer